Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CAMP4 THERAPEUTICS CORPORATION (CAMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: CAMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.4
1 Year Target Price $10.4
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.34% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 200.18M USD | Price to earnings Ratio - | 1Y Target Price 10.4 |
Price to earnings Ratio - | 1Y Target Price 10.4 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 1.30 - 7.79 | Updated Date 11/14/2025 |
52 Weeks Range 1.30 - 7.79 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1654.97% |
Management Effectiveness
Return on Assets (TTM) -61.85% | Return on Equity (TTM) -172.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 235349559 | Price to Sales(TTM) 80.03 |
Enterprise Value 235349559 | Price to Sales(TTM) 80.03 | ||
Enterprise Value to Revenue 61.9 | Enterprise Value to EBITDA - | Shares Outstanding 46881134 | Shares Floating 22795951 |
Shares Outstanding 46881134 | Shares Floating 22795951 | ||
Percent Insiders 17.96 | Percent Institutions 49.49 |
About CAMP4 THERAPEUTICS CORPORATION
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2024-10-11 | CEO, President & Director Mr. Joshua Mandel-Brehm | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.camp4tx.com |
Full time employees 55 | Website https://www.camp4tx.com | ||
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.